Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) is an indication for drug development with over 90 pipeline drugs currently active. According to GlobalData, preregistered drugs for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) overview
Radiation toxicity (also known as radiation sickness) is an acute illness caused by irradiation of the entire body by a high dose of ionizing radiation over a very short period of time (usually a matter of minutes). The root cause of this syndrome is depletion of immature parenchymal stem cells in specific tissues. Symptoms include bleeding from the nose, mouth, gums, and rectum; bloody stool; bruising; confusion; dehydration; diarrhea; fainting; and fatigue.
For a complete picture of PTSR and LoA scores for drugs in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
